A shift in investigational immunotherapy targets:

"Conversely, the number of phase 1 and phase 3 trials increased by 8.8% and 6.6%, respectively. Among all trials, there was a 10.3% decrease in those using PD-1/PD-L1 inhibitors, whereas other targets like CTLA-4, LAG-3, and CD3 T cell-engager increased 17.9%, 36.8%, and 13.3%, respectively."

https://www.cancerresearch.org/media-room/2023/immunotherapy-drug-development-pipeline-shifts-from-traditional-therapies-to-newer-modalities?utm_source=Facebook&utm_medium=Social&utm_campaign=CRI